Search Results
Jan 29, 2026, 08:05 ET Skyhawk Therapeutics 公佈其用於治療 Huntington 疾病的藥物 SKY-0515 於第 1 期臨床試驗中 受試患者的九個月中期結果。
90名患者服用 SKY-0515。 SKY-0515 是 Skyhawk 首種接受臨床試驗的藥物。Skyhawk 預計到 2027 年底，將推動更多的小分子藥物進入臨床試驗階段，用於治療目前尚無核准疾病改善療法的罕見神經系統疾病。關於 SKY-0515 第 1 期臨床研究 SKY-0515 第 1 期臨床試驗是一項首次人體試驗，旨在評估 SKY-0515 在健康志願者和早期Huntington 疾病 (HD) 患者中的安全性、耐受性、藥物動力學和藥效學。 試驗分為三部分。 A 部分和 B 部分評估 SKY-0515
More news about: Skyhawk Therapeutics
Jan 29, 2026, 08:00 ET NHS launches a single end-to-end lung cancer diagnostic pathway initiative with Optellum
https://www.telegraph.co.uk/news/2026/01/27/robots-spare-lung-cancer-patients-distress-of-repeated-test/[2] First reported by Sky News:
More news about: Optellum
Jan 29, 2026, 07:48 ET A Skyhawk Therapeutics anuncia resultados provisórios de nove meses em pacientes de seu ensaio clínico de fase 1 do SKY-0515 como tratamento para a doença de Huntington
mutante.A Skyhawk também anuncia hoje que seu ensaio clínico SKY-0515 Fase 2/3 FALCON-HD, realizado em doze centros na Austrália e Nova Zelândia, foi ampliado para todo o mundo. A Skyhawk já administrou SKY-0515 a mais de 90 pacientes. O SKY-0515 é o primeiro medicamento Skyhawk em ensaios clínicos.A
More news about: Skyhawk Therapeutics
Jan 29, 2026, 07:46 ET Skyhawk Therapeutics anuncia resultados provisionales de nueve meses en pacientes de su ensayo clínico de fase 1 de SKY-0515 como tratamiento para la enfermedad de Huntington
Huntington. SKY-0515 también ha demostrado una excelente exposición al sistema nervioso central y ha sido generalmente seguro y bien tolerado.A los tres, seis y nueve meses, los pacientes que recibieron SKY-0515 en la cohorte de pacientes de la parte C del ensayo clínico de fase 1 de SKY-0515, demuestran
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:57 ET Skyhawk Therapeutics gibt Neun-Monats-Zwischenergebnisse bei Patienten aus der klinischen Phase-1-Studie mit SKY-0515 zur Behandlung der Huntington-Krankheit bekannt
gab heute außerdem bekannt, dass die Phase-2/3-Studie SKY-0515 mit FALCON-HD, die an zwölf Standorten in Australien und Neuseeland läuft, weltweit ausgeweitet wurde. Skyhawk hat inzwischen mehr als 90 Patienten mit SKY-0515 behandelt. SKY-0515 ist das erste Medikament von Skyhawk, das sich
More news about: Skyhawk Therapeutics
Jan 28, 2026, 12:09 ET Skyhawk Therapeutics Umumkan Hasil Sementara Uji Klinis SKY-0515 Tahap 1 Selama Sembilan Bulan Pada Pasien Sebagai Pengobatan Penyakit Huntington
Skyhawk juga mengumumkan bahwa uji coba FALCON-HD Tahap 2/3 SKY-0515 yang dibuka di dua belas lokasi di Australia dan Selandia Baru, telah diperluas ke seluruh dunia. Kini Skyhawk memberikan dosis SKY-0515 kepada lebih dari 90 pasien. SKY-0515 adalah obat pertama dari Skyhawk yang sedang dalam
More news about: Skyhawk Therapeutics
Jan 28, 2026, 11:54 ET Skyhawk Therapeutics annonce les résultats intermédiaires à neuf mois de son essai clinique de Phase 1 du SKY-0515 comme traitement de la maladie de Huntington
Huntington. Le SKY-0515 a également démontré une excellente exposition du système nerveux central et était généralement sûr et bien toléré.Après trois, six et neuf mois, les patients recevant le SKY-0515 choisis parmi la cohorte de patients de la Partie C de l'essai clinique en Phase 1 du SKY-0515, montrent
More news about: Skyhawk Therapeutics
Jan 28, 2026, 11:21 ET Bozeman Continues to Draw National Attention as Out-of-State Buyers Drive 2025 Migration Trends
mountain access, and a return to community-driven values, as reported by Tamara Williams & Company. According to data released by Big Sky Country MLS, more than 25% of residential sales in 2025 were completed by out-of-state buyers, a trend that is actively shaping inventory, pricing,
More news about: Tamara Williams and Company
Jan 28, 2026, 10:34 ET Arcos und OverIT kündigen Integrations- und Vertriebspartnerschaft an, um den Außendienst von Versorgungsunternehmen zu optimieren
Berichterstattung und Wiederherstellung.Arcos genießt das Vertrauen von mehr als 200 Versorgungsunternehmen und unterstützt Organisationen dabei, Blue-Sky- und Gray-Sky-Betrieb zu steuern, indem es sich in unterschiedliche Systeme integriert und so eine Situationsübersicht in Echtzeit über vernetzte Systeme hinweg
More news about: ARCOS
Jan 28, 2026, 10:00 ET Maeva Launches Science-Backed Nutrition Line Designed Exclusively for GLP-1 Users
building long-term habits and sustainable results.Founded by veterans of the consumer wellness and digital commerce space—including leaders behind Sky Organics', Maeva brings deep expertise in brand building, e-commerce, and performance marketing to the rapidly evolving metabolic health category."Our
More news about: Maeva
Jan 28, 2026, 08:52 ET Frame It Easy Introduces Smart Color Matching: Precision Framing for Designers, Brands, and Creative Spaces
mats.Design from the art itself.Using the Color Picker tool, users can match color directly from an uploaded piece, whether that's the sky in a photograph, a brushstroke in a painting, or the exact shade of brown in a pet's portrait.Move faster with built-in guidance.Paired
More news about: Frame It Easy
Jan 28, 2026, 07:00 ET Fisher Investments Recognized for Excellence in Employee Training and Development
more total reach than any other, non-syndicated columnist of any type ever. Ken appears regularly on major TV news like Fox Business and News, BBC, Sky News, BNN Bloomberg and CNN International. Ken has written 11 investing and finance books, including four New York Times bestsellers. For more
More news about: Fisher Investments
Jan 28, 2026, 04:14 ET Компания Skyhawk Therapeutics объявляет промежуточные результаты за девять месяцев среди пациентов клинического исследования фазы 1 препарата SKY-0515 для лечения болезни Гантингтона
исследование фазы 2/3 FALCON-HD препарата SKY-0515, начатое в двенадцати центрах в Австралии и Новой Зеландии, распространилось по всему миру. К настоящему времени компания Skyhawk предоставила дозы препарата SKY-0515 более чем 90 пациентам. SKY-0515 — это первый препарат Skyhawk, проходящий
More news about: Skyhawk Therapeutics
Jan 28, 2026, 03:50 ET Skyhawk Therapeutics、ハンチントン病治療薬SKY-0515の第I相臨床試験における患者の9か月中間結果を発表
SKY-0515の投与により、血中のmHTTタンパク質は9mgの投与で62％減少し、PMS1 mRNAは26％減少するという用量依存的な効果が明らかとなりました。PMS1は体細胞CAGリピート拡大とHDの病態を左右する重要な要素です。また、SKY-0515は優れた中枢神経系への影響力を示し、全般的に安全で忍容性も良好な結果となりました。SKY-0515の第I相臨床試験のパートC患者コホートにおいて、SKY-0515を投与した患者は、3か月、6か月、9か
More news about: Skyhawk Therapeutics
Jan 28, 2026, 03:11 ET Společnost Skyhawk Therapeutics oznamuje průběžné výsledky za devět měsíců u pacientů z 1. fáze klinického hodnocení přípravku SKY-0515 pro léčbu Huntingtonovy choroby
vysokou dávku přípravku SKY-0515. Mezi cíle studie patří hodnocení mutantního proteinu HTT a mRNA PMS1. Prvním pacientům byla dávka SKY-0515 v části C podána v lednu 2025. Zařazení do fáze 1C studie SKY-0515 je nyní ukončeno.O klinické studii FALCON-HD fáze 2/3 SKY-0515 FALCON-HD
More news about: Skyhawk Therapeutics
Jan 28, 2026, 00:00 ET When a Fragrance Returns With a Memory ARMAF Introduces Odyssey Mandarin Sky Vintage at Cosmoprof Miami 2026
rediscovered. They come back shaped by time, carrying familiarity while offering something deeper and more reflective. With Odyssey Mandarin Sky Vintage, ARMAF revisits one of its most recognizable creations through a softer, more nuanced lens. The fragrance will be unveiled at Cosmoprof Miami
More news about: Armaf
Jan 27, 2026, 22:10 ET Spoločnosť Skyhawk Therapeutics oznamuje predbežné výsledky u pacientov z fázy 1 klinického skúšania lieku SKY-0515 za deväť mesiacov liečby Huntingtonovej choroby
dnes tiež oznámila, že jej klinické skúšanie lieku SKY-0515 fázy 2/3 FALCON-HD, ktoré prebieha na dvanástich miestach v Austrálii a na Novom Zélande, sa rozšírilo do celého sveta. Spoločnosť Skyhawk už podala liek SKY-0515 viac ako 90 pacientom. SKY-0515 je prvý liek od spoločnosti Skyhawk, ktorý
More news about: Skyhawk Therapeutics
Jan 27, 2026, 21:04 ET /C O R R E C T I O N -- ARCOS/
and dispatch through execution, reporting, and recovery.Trusted by more than 200 utilities, Arcos enables organizations to manage blue-sky and gray-sky operations by integrating with disparate systems to drive real-time situational awareness across connected systems. By connecting work execution
More news about: ARCOS
Jan 27, 2026, 20:34 ET /C O R R E C T I O N -- ARCOS/
and dispatch through execution, reporting, and recovery.Trusted by more than 200 utilities, Arcos enables organizations to manage blue-sky and gray-sky operations by integrating with disparate systems to drive real-time situational awareness across connected systems. By connecting work execution
More news about: ARCOS
Jan 27, 2026, 19:16 ET Alexandria Real Estate Equities, Inc. Announces Cash Tender Offers
jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. In any jurisdiction in which the securities laws or blue sky laws require the Tender Offers to be made by a licensed broker or dealer, the Tender Offers will be
More news about: Alexandria Real Estate Equities, Inc.
Jan 27, 2026, 16:00 ET Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.www.innocanpharma.com For
More news about: Innocan Pharma Corporation
Jan 27, 2026, 16:00 ET Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.www.innocanpharma.com For
More news about: Innocan Pharma Corporation
Jan 27, 2026, 15:16 ET Cloudbound™ Opens in New Rochelle, NY: A New Playspace for Families with Toddlers and Little Kids Ages 0-6
Imagined by the same parent company as Sky Zone® trampoline parks and designed in partnership with the country's leading childhood development experts, Cloudbound combines the energy
More news about: Cloudbound
Jan 27, 2026, 12:24 ET ELEVATE YOUR DAILY ROUTINES WITH TWO NEW INNOVATIONS FROM PACKIT®
commute, a balanced snack for a post-workout recovery, or a hearty lunch to stay fueled for a long shift, this bag is the perfect fit. Available in Sky Blue/Azure Blue and Papaya/Poppy."At PackIt, we believe that health is built on the foundation of daily habits," says Laci Wilson, VP of Product
More news about: PackIt
Jan 27, 2026, 11:05 ET North Dakota Shines: A Year-Round Destination for Rare Natural Phenomena
Front-row access to spectacles shaped by sky, ice and open prairies abound in North DakotaBISMARCK, N.D., Jan. 27, 2026 /PRNewswire/ -- Travelers seeking awe-inspiring natural phenomena will find
More news about: North Dakota Tourism Division